Johnson & Johnson Inc. is one
of the leaders in the global pharmaceutical industry with 36% of the market
share in the United States alone. Johnson & Johnson has adapted a very
unique and successful business model. The company highly supports
diversification in both its products and its target consumer. They offer
hundreds of different kinds of products to people of all ages, genders, and
various needs all over the world. The Johnson & Johnson website claims that
they have great responsibility in this expanding global environment by reaching
out to more and more people everyday, everywhere. The company is a strong
multi-national company with operations in over 57 countries. Even with its
large customer base of household products, Johnson & Johnson’s top market
is its pharmaceuticals, which includes its flagship product Remicade.
Johnson & Johnson’s financial statement for 2010 reported revenue of $61.6 Billion, down $200 Million from 2009 but up $2 Billion from 2008. Total company assets increased from $94.7 Billion in 2009 to $102.9 Billion last year. The company experienced a huge $10 Billion growth between 2005 and 2007 and eventually it became a steady growth through the recession, however the recession did not cause any negative consequences in growth. In fact, the net income has growth significantly as well without any dips. From 2007 to 2010 the company gained $3 Billion in net income. Cash flow has also steadily increased over the years; from $12.5 Billion in 2005 to $16.3 Billion last year. Current company liabilities have consequently increased too; from $20.9 Billion in 2008 to $23.1 Billion last year.
Johnson & Johnson’s financial statement for 2010 reported revenue of $61.6 Billion, down $200 Million from 2009 but up $2 Billion from 2008. Total company assets increased from $94.7 Billion in 2009 to $102.9 Billion last year. The company experienced a huge $10 Billion growth between 2005 and 2007 and eventually it became a steady growth through the recession, however the recession did not cause any negative consequences in growth. In fact, the net income has growth significantly as well without any dips. From 2007 to 2010 the company gained $3 Billion in net income. Cash flow has also steadily increased over the years; from $12.5 Billion in 2005 to $16.3 Billion last year. Current company liabilities have consequently increased too; from $20.9 Billion in 2008 to $23.1 Billion last year.
Johnson & Johnson is one of the top five key industry players. It owns a huge chunk of the US pharmaceutical market and is inching its way over to a bigger global market share in the next couple years through its diversification strategy and the production of generic medication.
Djeki Bidjerano
Sources:
http://finance.yahoo.com/q/ks?s=JNJ
http://www.netadvantage.standardandpoors.com.proxyau.wrlc.org/NASApp/NetAdvantage/cp/companyFinancials.do
http://www.investor.jnj.com/2010annualreport/chairman/pharmaceuticals.html
http://www.wikinvest.com/stock/JOHNSON_%26_JOHNSON_(JNJ)
No comments:
Post a Comment